Gland Pharma gets USFDA nod for generic Sugammadex Injection

Gland Pharma gets USFDA nod for generic Sugammadex Injection. This approval allows Gland Pharma to launch its generic version of Sugammadex Injection in the U.S. market. Sugammadex, used to reverse neuromuscular blockade, has a market size of over $200 million annually. The move strengthens Gland's position in the sterile injectables segment.

📊 STOCKS: $GLAND | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA